Understanding how long a drug stays in the body helps explain why certain antidepressants require different dosing considerations. Tricyclic antidepressants have notably long and variable half-lives because they are extensively metabolized by the liver and often form active metabolites. This leads to a T1/2 that can span roughly from 16 up to 80 hours, depending on the specific drug and individual differences in metabolism. This wide range is less typical for the other classes. Non-benzo hypnotics tend to have short half-lives—measured in hours—to minimize next-day sedation. SSRIs and SNRIs generally cluster around a day or more, with some values in the 1–3 day range (fluoxetine being a notable exception with a longer duration). Benzodiazepines show a broad range as well, but their typical patterns don’t define a single broad 16–80 hour span across the whole class like tricyclics do. So the broad and variable 16–80 hour half-life is characteristic of tricyclic antidepressants, reflecting their metabolism and active metabolites.

The important point is that electrical fires involve energized equipment, so you need an extinguisher that won’t conduct electricity or worsen the hazard. An extinguisher designated for electrical fires uses non-conductive extinguishing agents, allowing you to attack the flame without creating an electrical shock risk. That makes it the best choice for an energized electrical fire. Extinguishers for ordinary combustibles are meant for materials like wood and paper and don’t address the electrical hazard. Those designed for flammable liquids target liquids and wouldn’t safely or effectively handle an energized electrical source. Metal fires require specialized agents and handling that aren’t appropriate for electrical equipment. So the electrical-fire–rated extinguisher is the one that aligns with the danger and safety considerations of fires involving live electricity. If it’s safe to do so, you should also try to de-energize the equipment before fighting the fire, and then call for help.

Movements that happen specifically during sleep are described with the term Periodic Limb Movements in Sleep, abbreviated PLMS. The phrase “in Sleep” sets the context as nocturnal phenomena observed during sleep studies, which is how this pattern is distinguished in sleep medicine. The other options either refer to the disorder rather than the movements, use nonstandard wording, or omit the sleep setting, making them less precise. So, Periodic Limb Movements in Sleep is the canonical term and the correct acronym.

Combining beta-adrenergic blocking with class III potassium channel blockade is what makes this drug stand out for atrial fibrillation. The beta-blocking action slows AV nodal conduction and reduces adrenergic triggers that can promote AF, while the class III effect prolongs repolarization, increasing the refractory period and helping maintain sinus rhythm. Amiodarone does have class III activity and some beta-blocking–like effects, but it is not primarily categorized as a beta-blocker; dofetilide is a pure class III blocker with no beta-blocking action; quinidine is class IA, not class III. Therefore, the drug that best fits both beta-blocker and class III antiarrhythmic properties used for AF is the one that uniquely combines both actions.